ERBB2 and breast carcinoma: Basal‐like breast cancers (BLBCs) underexpress estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) and encompass 60–90% of triple‐negative (ER−/PR−/HER2−) breast cancers.